Skip to main content

ASH Highlights

Meeting Highlights

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

Meeting Highlights

Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis

Meeting Highlights

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Meeting Highlights

Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma

Meeting Highlights

Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies

Charles Bankhead, Medical Writer

Meeting Highlights

MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL

Phoebe Starr, Medical Writer

Meeting Highlights

Researchers Identify First Mutation to Explain Resistance to Venetoclax

Phoebe Starr, Medical Writer

Meeting Highlights

Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy

Phoebe Starr, Medical Writer

Meeting Highlights

Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas

Phoebe Starr, Medical Writer

Meeting Highlights

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL

Wayne Kuznar, Medical Writer

1
2
3
4

Page 3 of 4
Results 21 - 30 of 37